Sutent: manufacturer, instruction on the use of the drug, price, patient testimonials, analogues

Sutent is an antitumor agent. The main active substance is sunitinib, which inhibits the activity of more than 80 different kinases.

Form release, formulation and packaging

Available in capsules with different active ingredient contents. The skin can be different in color:

  • red - 12.5 mg,
  • brown-orange - 25 mg,
  • orange - 50 mg.

The inscription on the capsule is made in white ink. Inside there are granules of yellow or orange color. Excipients: mannitol, povidom, magnesium stearate, croscarmellose sodium. The shell is made of gelatin and titanium dioxide.

Available in vials of 28-30 pieces. The cardboard pack contains 1 bottle. The release form can also be in blisters. In this case, there are 4 blisters in the cardboard bundle.

Manufacturer

Sutent is produced by the Italian corporation Pfizer Italia S.r. L.(Pfizer Italy Srl).

Indications for use

Used in the absence of the effect of taking cytokines in renal cell carcinoma with metastases. Indications fo

r use are gastrointestinal stromal tumors with resistance or hypersensitivity to Imatinib.

Contraindications

Efficacy and safety in the treatment of children The patient is not identified. Contraindications:

  • adverse reactions to drug components,
  • Hepatic, cardiac, renal failure( severe),
  • Pregnancy and lactation.

Used with caution in patients with heart disease, bradycardia or electrolyte imbalance.

Mechanism of action

The active substance inhibits the kinase receptors responsible for the growth of formation, the formation of malignant cells in other organs. It is an inhibitor of growth factor and stem cells.

During treatment, suppression of tumor growth occurs even with regression. Metabolite activity is similar to that of sunitinib.

When taken is well absorbed. After 6-11 hours the amount of active substance in the blood reaches the maximum markings. The intake of food does not affect the pharmacokinetics. The degree of communication with proteins reaches 95%.With repeated administration, accumulation is observed 3-4 times.

Instruction for use of the drug

Suspension The regimen depends on the characteristics of the cancer:

  1. Stromal gastrointestinal tumors - the recommended dose is 50 mg per day for a total of 4 weeks. Then a break for 14 days.
  2. The renal cell carcinoma is 50 mg per day for a month.
  3. Inoperable or metastatic neuroendocrine tumors of people with disease progression - 37.5 mg daily without interruptions.

If the reception was missed, do not take capsules further.

Depending on the tolerability, the dose can be adjusted to 12.5 mg more or less. Older patients are not subject to dose changes.

Side effects of

Undesirable effects depend on the general condition of the body and the characteristics of the disease. The most serious side effects are:

  • pulmonary embolism,
  • thrombocytopenia,
  • tumor bleeding,
  • febrile neutropenia,
  • arterial hypertension.

With venous thrombosis patients, venous thromboembolism was observed in patients.

Overdose

There is no specific antidote. Therefore, a symptomatic treatment is prescribed, which consists of rinsing the stomach and inducing vomiting reactions.

Special instructions

Before starting therapy, it is necessary to conduct a study of hematological parameters.

There have been reports of bleeding events leading to death. These manifestations are unexpected. Therefore, it is necessary to periodically inspect and assess blood counts.

In anticoagulant therapy, blood coagulability is monitored.

Thyroid gland studies are conducted in people with hypo- hyperthyroidism. Treatment is carried out in accordance with medical practice before treatment.

Compatibility of

The use of the Sutene together with inhibitors of the isoenzyme CYP3A4 leads to an increase in the concentration of the active component in the blood. With the simultaneous use of this antitumor drug with cathonazole, the active metabolite content may increase.

Therefore, it is recommended not to allow the simultaneous administration of the Sutent with inhibitors of CYP3A4, choosing an alternative treatment regimen. If this is not possible, the daily dose should be reduced by 12.5 mg, but not less than 37.5 mg.

Patient feedback

For many patients, the use of the drug is difficult due to its high cost. Moscow is the only city where you can get the medicine for free. But only a small number of cancer patients can count on this.

The price of a medicine in Moscow

The cost of a drug in the capital depends on the dosage. Sutent 50 mg can be bought from 185,000 rubles to 252,000 for 28 pieces. Capsules in 12.5 mg are sold for 60-80 thousand rubles. The cost of the Sutent 25 mg is twice as high.

Analogues Sutent

  • Tarceva,
  • Torizel,
  • Sprite,
  • Tasigne,
  • Vargatef.

Synonyms

Giotrif, Histamel, Cotellic, Xalcory, Spiralel, Tayverb.

Conditions for dispensing from pharmacies

Prescription is released.

Storage conditions and shelf life

It is allowed to store the drug for no more than two years at a temperature of up to 25 degrees.

  • Share